A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

Novo Nordisk’s (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively ...

Novo Nordisk’s NOVO.B1.17%increase; green up pointing triangle Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish ...

Some pros say the Fed is likely to make rate cuts in 2026. Indeed, with the Fed’s first meeting of the year not scheduled until Jan. 28, the CME FedWatch tool currently predicts a 14.4% chance that ...

American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices for the drug, called the Wegovy ...

Novo launches Wegovy pill in competitive obesity drug market Eli Lilly expects weight-loss pill decision later this year Novo targets self-pay market with oral option over injectable Starter dose of ...

Novo Nordisk’s wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the United States. The pill is available in four doses and is cheaper ...

For years, pharmaceutical companies have been racing to develop a market-ready GLP-1 weight-loss pill to join the ranks of popular injectables. Today, Novo Nordisk’s oral version of Wegovy is ...

The Wegovy pill is the first and only oral GLP-1 for weight loss in adults. The first and only oral GLP-1 for weight loss in adults is now available to consumers. Drugmaker Novo Nordisk announced ...

Jan. 5 (UPI) --Pharmaceutical company Novo Nordisk announced Monday that a new pill-version of its GLP-1 weight-loss drug is now "broadly available" at U.S. pharmacies. The Wegovy pill, available in ...

A daily pill for weight loss has officially arrived in the U.S. On Monday, Novo Nordisk rolled out the first GLP-1 weight-loss pill, an oral version of Wegovy. The company says the new option is ...

Novo Nordisk A/S is rated a buy, driven by FDA approval of its oral Wegovy, strong fundamentals, and attractive valuation versus Eli Lilly. Recent clinical data and first-mover advantage position ...